Common Contracts
2 similar Clinical Study Agreement contracts
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉ STUDII PROTOCOL: K-877 -301 PROTOKOL: K-877- 301 SITE: 19005 PRACOVIŠTĚ: 19005 INSTITUTION AGREEMENT XXXXXX SMLOUVA ZDRAVOTNICKÉHO ZAŘÍZENÍXXXXX KOWA RESEARCH INSTITUTE, INC KOWA RESEARCH INSTITUTE, INC. 28...Clinical Study Agreement • July 11th, 2017
CLINICAL STUDY AGREEMENTThis clinical study agreement (“Agreement”), effective as of 28-June-2017 (the “Effective Date”), is entered into by and among Medpace, Inc., with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”), represented by XXXXX Clinical Trial Manager; Vseobecna fakultni nemocnice v Praze, with its principal office and place of business at U Nemocnice 499/2, 128 08 Prague 2, Czech Republic ("Institution”), represented by XXXXX, Director. Medpace and Institution, are sometimes collectively referred to herein as parties (the “Parties”). Parties agree that XXXXX,with his permanent residence at XXXXX, Czech Republic (“Investigator”) shall serve as the principal investigator in the Study. WHEREAS, Kowa Research Institute, Inc. (“Sponsor”) is sponsoring a clinical study on K- 877, (the “Study Drug”), in accordance with Protocol No. K-877-301, titled “A Phase 3, Multi- Center, Placebo-Controlled, Randomized, Double- Blind, 12-Week
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉ STUDII PROTOCOL: K-877 -303 PROTOKOL: K-877- 303 SITE: 19005 PRACOVIŠTĚ: 19005 INSTITUTION AGREEMENT XXXXX SMLOUVA ZDRAVOTNICKÉHO ZAŘÍZENÍXXXXX KOWA RESEARCH INSTITUTE, INC KOWA RESEARCH INSTITUTE, INC. 28 -...Clinical Study Agreement • July 11th, 2017
CLINICAL STUDY AGREEMENTThis clinical study agreement (“Agreement”), effective as of 28-June-2017 (the “Effective Date”), is entered into by and among Medpace, Inc., with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”), represented by XXXXX, Clinical Trial Manager; Vseobecna fakultni nemocnice v Praze, with its principal office and place of business at U Nemocnice 499/2, 128 08 Prague 2, Czech Republic ("Institution”), represented by XXXXX, Director. Medpace and Institution, are sometimes collectively referred to herein as parties (the “Parties”). Parties agree that XXXXX,with his permanent residence at XXXXX, Czech Republic (“Investigator”) shall serve as the principal investigator in the Study. WHEREAS, Kowa Research Institute, Inc. (“Sponsor”) is sponsoring a clinical study on the compound K-877 (the “Study Drug”), in accordance with Protocol No. K-877-303, titled “A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blin
